Download PDF Introduction The pharmaceuticals sector has been the center of attention lately for the successful vaccines trial that finally gave some hope of recovery, even though it wasn’t without controversies. However, a lot more has been going on in the industry that might change the reputation that the industry Read more…
Introduction A persistent financial crisis, the rising of regional tensions, the concerns of a trade war and many other facts have recently been catching up with the M&A-friendly international environment. Protectionism seems now to pervade the new world order. Rising economic nationalism is threatening to impact M&A activity across all Read more…
Allergan PLC (NYSE: AGN) – market cap as of 16/02/2017: $82.86bn Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ) – market cap as of 16/02/2017: $2.23bn Introduction On February 13, 2017, the biopharmaceutical giant Allergan PLC announced that it entered into an agreement to purchase the medical technology company Zeltiq Aesthetics Inc. in Read more…
Allergan (AGN) – Market cap as of 07/10/2016: $94.6bn About Allergan Allergan plc is a diversified global pharmaceutical company headquartered in Dublin, Ireland. It is considered to be a leader in “growth pharma”, after its newfound focus on branded pharmaceuticals. Since 2007 Allergan has made a number of acquisitions to Read more…
Introduction M&A activity in 2015 has surpassed the peak from 2007 driven by deals in pharmaceuticals, energy, and consumer sector. Many of the factors that helped the dealmakers in 2015 are still in place, but the bond market turmoil and geopolitical instability might play a role in 2016 together with Read more…
Mylan N.V.; market cap as of 12/02/2016: $20.54bn Meda AB; market cap as of 12/02/2016: kr52.44bn ($6.24bn) Introduction On February 10, Mylan NV (NASDAQ: MYL.O) announced its acquisition of Meda AB (STO: MEDAa.ST) in a deal worth $7.2bn made of cash and stock, while the latter reported an unexpected slowdown Read more…
Pfizer Inc.; market cap as of 27/11/2015: $202.7bn Allergan plc; market cap as of 27/11/2015: $126bn Introduction On November 23, 2015, Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) announced that their boards of directors have unanimously approved a definitive merger agreement under which Pfizer will combine with Read more…
Valeant Pharmaceuticals; Market Cap: $25.73bn (as of 13/11/2015) Introduction Valeant Pharmaceutical, a pharma behemoth renowned for its aggressive acquisition strategy, has been facing some hard times as its stellar performance has deteriorated considerably amid scrutiny over its monopoly pricing for its drugs as well as recent accusations for its Read more…
Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…
Pershing Square Holdings Market Cap (as of 31/10/2014): $6.181bn Pershing Square Holdings, the hedge fund company founded in 2003 by Bill Ackman, the activist investor and Harvard alumnus who boasts a $1.2bn net worth, raised $2.73bn floating for the first time in the Euronext Amsterdam on October 13th. The fund, Read more…
Valeant Pharmaceuticals International; Market Cap. (as of 3/10/2014): $42.9bn Allergan Inc.; Market Cap. (as of 3/10/2014): $53.64bn As low debt obligations alongside large cash holdings and patent expiration liabilities continue to foster a conducive environment for M&A activity in the pharmaceutical and biotech industry another multi-billion dollar struggle has emerged: Read more…
Pfizer Inc, Market Cap (as of 23/05/2014): $188.37bn AstraZeneca PLC, Market Cap (as of 23/05/2014): $91.78bn In its bid for AstraZeneca, Pfizer, the famous Viagra producer, failed to make a satisfactory offer and turned the potential biggest foreign takeover in UK corporate history into failure. It all happened on May Read more…